Prognostic value of c-erbB-2 expression in uterine cervical carcinoma.

Abstract

Aims: To study the pattern of expression and prognostic importance of c-erbB-2 protein in cervical carcinoma. Methods: Sixty two cases of stage IB/IIA cervical carcinoma, representing the three main tumour types, were investigated immunohistochemically for the presence ofc-erbB-2 protein expression, using a monoclonal antibody (CB 1) to its internal domain. Follow up of at least five years' duration was available in all cases. Results: Definite membrane staining was seen in 38-7% of cases. There was a strong correlation with poor survival (p < 0.0001) particularly. For those with adenocarcinomas, this was the case when nodal metastases were present. In contrast, for squamous carcinomas and adenosquamous carcinomas, the association with a poor prognosis was most apparent in those patients without lymph node metastases.Conclusions: These findings raise the possibility that immunostaining for c-erbB-2 protein could be used as a prognostic marker and may help identify those patients for whom early adjuvant treatment might be beneficial.

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

“…In endometrial adenocarcinoma the miRNA, miR-125b, inhibits the expression of HER2/neu and has been noted to be downregulated in HER2/neu-overexpressing endometrial adenocarcinoma samples [428]. Squamous cell carcinoma of the uterine cervix also expresses HER2/neu in 20-30% of the cases [10,377,415,[429][430][431][432][433][434][435][436][437] with approximately 50-75% of those cases demonstrating gene amplification [438][439][440][441][442]. Gene amplification is positively associated with the presence of HPV-6, a low -risk HPV serotype, in the cervical biopsies [443].…”

“…Gene amplification is positively associated with the presence of HPV-6, a low -risk HPV serotype, in the cervical biopsies [443]. Expression of HER2/neu in squamous cell carcinoma of the cervix has been associated with a poor prognosis [435][436][437][438]444] and an increased risk of recurrence after radiation therapy [444]. Carcinosarcoma has approximately the same percentage of HER2/neu overexpression as cervical squamous cell carcinoma despite its more aggressive clinical course [295,297,[445][446][447] and this expression is closely associated with the carcinoma component [445,446].…”

Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens

“…Immunohistochemical demonstration of neuroendocrine differentiation (di Sant 'Agnese & de Mesy Jensen, 1987;Cohen et al, 1991), c-erbB-2 protein (Gullick et al, 1991;Reilly et al, 1991;Hale et al, 1992), p53 protein (Porter et al, 1992) and PSA (Hammond et al, 1989;Bazinet et al, 1992) have also been related to tumour growth.…”

Prostatic carcinoma: a multivariate analysis of prognostic factors

“…Immunohistochemical demonstration of neuroendocrine features (di Sant'Agnese & de Mesy Jensen, 1987;Cohen et al, 1991), c-erbB-2 protein (Gullick et al, 1991;Reilly et al, 1991;Hale et al, 1992), p53 protein (Porter et al, 1992), prostate acid phosphatase (PAP) (Sakai et al, 1991), prostate-specific antigen (PSA) (Hammond et al, 1989;Bazinet et al, 1992) and vimentin (Leong et al, 1988) has been related to tumour prognosis. However, at present there is no general agreement concerning the best combination of prognostic factors.…”